IPXL - Impax Laboratories, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
18.30
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.30
Open18.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.40 - 18.95
52 Week Range17.40 - 18.95
Volume3,041,017
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire3 months ago

    ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax

    BAUDETTE, Minn. , May 7, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related ...

  • Amneal and Impax Complete Business Combination
    PR Newswire3 months ago

    Amneal and Impax Complete Business Combination

    ‒ Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States ‒ ‒ Combined First Quarter 2018 Total Revenues of $418 Million ; GAAP Net Loss of $79 million ; Adjusted ...

  • PR Newswire4 months ago

    Apergy Set to Join S&P MidCap 400; 3D Systems to Join S&P SmallCap 600

    NEW YORK , May 2, 2018 /PRNewswire/ -- Apergy Corp. (NYSE: APY) will replace 3D Systems Corp. (NYSE: DDD) in the S&P MidCap 400, and 3D Systems will replace Impax Laboratories Inc. (NASD: IPXL) in the ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Impax Launched a Generic Version of Estrace(R) Cream

    Stock Monitor: Rockwell Medical Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free research report on Impax Laboratories, Inc. (NASDAQ: IPXL ...

  • PR Newswire4 months ago

    Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)

    There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see WARNINGS, Malignant Neoplasms, Endometrial Cancer].

  • ACCESSWIRE5 months ago

    Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress(TM)

    Stock Monitor: Impax Laboratories Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Assembly Biosciences, Inc. (NASDAQ: ...

  • Impax Shareholders Approve Proposed Business Combination with Amneal
    PR Newswire5 months ago

    Impax Shareholders Approve Proposed Business Combination with Amneal

    "We appreciate the strong support we have received from Impax shareholders for our transformational combination with Amneal," said Paul Bisaro, President and Chief Executive Officer of Impax. "Today's approval represents an important milestone in the process to combine our two organizations and create a diversified pharmaceutical company with stronger capabilities and greater resources.

  • Amneal Gains Approval for Erythromycin Tablets USP
    PR Newswire5 months ago

    Amneal Gains Approval for Erythromycin Tablets USP

    BRIDGEWATER, N.J. , March 14, 2018 /PRNewswire/ --  Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths.  The Amneal product is a therapeutic equivalent ...

  • PR Newswire5 months ago

    Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference

    BRIDGEWATER, N.J., March 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL) today announced that they will jointly present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, Florida on Tuesday, March 13, 2018 at 2:35 p.m. ET. Paul Bisaro, President and CEO of Impax, Bryan Reasons, Senior Vice President and Chief Financial Officer of Impax, and Robert Stewart, President of Amneal Pharmaceuticals will participate in a fireside chat. To access a live webcast of the presentation, visit Impax's Investor Relations Web site at https://investors.impaxlabs.com/Investor-Relations.

  • Amneal Launches Generic for Tamiflu® Oral Suspension
    PR Newswire6 months ago

    Amneal Launches Generic for Tamiflu® Oral Suspension

    BRIDGEWATER, N.J. , March 1, 2018 /PRNewswire/ --  Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company's AB-rated therapeutic equivalent for Tamiflu ® , in a 6 mg/mL ...

  • ACCESSWIRE6 months ago

    Impax Laboratories, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Impax Laboratories, Inc. (NASDAQ: IPXL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 8:30 AM Eastern Time. ...

  • Impax Reports Fourth Quarter and Full Year 2017 Results
    PR Newswire6 months ago

    Impax Reports Fourth Quarter and Full Year 2017 Results

    - Q4 2017 Total Revenues of $183 Million ; GAAP Net Loss Per Share of $4.18 ; Non-GAAP Adjusted Income Per Share of $0.11 - - Full Year 2017 Total Revenues of $776 Million ; GAAP Net Loss Per Share of ...

  • Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®
    PR Newswire6 months ago

    Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

    BRIDGEWATER, N.J. , Feb. 21, 2018 /PRNewswire/ --  Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company's AB-rated equivalent for Namenda XR ® , in 7 mg, 14 ...

  • Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
    PR Newswire6 months ago

    Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets

    Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.

  • PR Newswire6 months ago

    Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations

    BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL), today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax. "We are pleased that Andy has joined Amneal and will be leading our commercial organization," said Chirag Patel, Co-CEO and chairman, Amneal Pharmaceuticals. Mr. Boyer will work closely with Chirag and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future CEO of the new Amneal, to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.

  • Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®
    PR Newswire6 months ago

    Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®

    BRIDGEWATER, N.J. , Feb. 5, 2018 /PRNewswire/ --  Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate ...

  • PR Newswire7 months ago

    CorePharma, LLC Acquired by Investor Group

    MIDDLESEX, N.J., Jan. 30, 2018 /PRNewswire/ -- A group of industry investors has announced the acquisition of CorePharma, LLC, its facilities and equipment in Middlesex, NJ from Impax Laboratories, Inc (IPXL). Henceforth, this ownership group will have 100% equity interest in CorePharma, LLC. Financial terms of the acquisition were not disclosed.

  • ACCESSWIRE7 months ago

    Blog Exposure - FDA Granted Final Approval to a Generic Version of Perrigo’s Estrace Cream

    LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Perrigo Co. PLC (NYSE: PRGO ). If you want access to this report all you need to do is sign ...

  • Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
    PR Newswire7 months ago

    Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream

    Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market.

  • Impax to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018
    PR Newswire7 months ago

    Impax to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018

    HAYWARD, Calif. , Jan. 16, 2018 /PRNewswire/ --  Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its fourth quarter and full year 2017 financial results on Thursday, ...

  • PR Newswire7 months ago

    Amneal Pharmaceuticals and Impax Laboratories to Present at the 36th Annual J.P. Morgan Healthcare Conference

    BRIDGEWATER, N.J., Jan. 3, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL) today announced that they will jointly present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 9, 2018. Paul Bisaro, President and CEO of Impax will present the presentation at 8:00 AM Pacific Time (11:00 AM Eastern Time). To access a live webcast of the presentation, visit Impax's Investor Relations Web site at https://investors.impaxlabs.com/Investor-Relations.

  • ACCESSWIRE8 months ago

    ACT NOW: Monteverde & Associates PC Announces An Investigation Of Impax Laboratories, Inc. - IPXL

    NEW YORK, NY / ACCESSWIRE / December 29, 2017 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...

  • PR Newswire8 months ago

    Impax Announces Sale of Taiwan Manufacturing Facility

    BRIDGEWATER, N.J., Dec. 19, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (IPXL) today announced that it has entered into a definitive agreement to sell its manufacturing facility in Taiwan ("Impax Taiwan") to Bora Pharmaceuticals Co, Ltd. ("Bora"). This sale supports Impax's operational and cost improvement plans to streamline operations and reduce costs. Under the terms of the agreement, Bora will purchase all of the issued share capital in Impax Taiwan and certain loans outstanding between Impax and Impax Taiwan for a total purchase price of $18.5 million.